期刊文献+

慢性心力衰竭患者血浆内脏脂肪素水平及其影响因素的研究 被引量:1

Serum visfatin level and its influencing factors in patients with chronic heart failure
下载PDF
导出
摘要 目的观察慢性左心衰竭患者的血浆内脏脂肪素水平,探讨其与糖脂代谢参数和高敏C反应蛋白(hs-CRP)的关系。方法将50例慢性左心功能不全患者(心力衰竭组)根据超声心动图左心室射血分数(LVEF)分成两亚组:轻度心功能不全亚组(35%<LVEF≤45%)25例.重度心功能不全亚组(LVEF≤35%)25例;对照组(LVEF>50%)24例,检测并比较各组hs-CRP、内脏脂肪素、血脂、血糖等指标。结果心力衰竭组内脏脂肪素较对照组降低(5.8±22.1 ng/ml vs 8 5±2 4 ng/ml。P<0 01);轻度、重度心功能不全亚组及对照组比较,内脏脂肪素、hs-CRP、血糖、HOMAIR、HDL-C差异均有统计学意义(P<0 05或0.01);内脏脂肪素与LVEF呈正相关(r=0.49,P<0.01),与hs-CRP呈负相关(r=-0.30,P<0.01)。结论心力衰竭患者的血清内脏脂肪素显著降低,此结果独立于年龄、性别、BMI和代谢参数。 Objective To determine the serum visfatin levels in patients with chronic heart failure (CHF) and its influencing factors. Methods Fifty patients with chronic heart failure due to left ventricular systolic dysfunction were divided into mild HF group (35%〈LVEF≤45%, n= 25) and severe HF group (LVEF≤35%, n=25); 24 healthy subjects (LVEF〉50%) served as control group. Serum visfatin, hsCRP, glucose and lipid metabolism parameters were measured in all subjects. Results Serum visfatin levels in HF groups were significantly lower than those in controt group (5.8 ±22.1ng/ml vs 8.5 ±2.4ng/ml, P〈0.01). The Kruskal-Wallis test showed significant differences among three groups in serum revels of visfatin, hsCRP, glucose, HOMAIR and HDL-cholesterol(P〈0.05 or 0.01). Serum visfatin level was positively correlated with LVEF and negatively correlated with hs-CRP (r=0.49, -0.30,P〈0.01). Conclusion Serum visfatin levels in patients with systolic HF are decreased, which is independent to age, sex, BMI, and metabolic parameters of patients.
出处 《浙江医学》 CAS 2014年第6期501-503,共3页 Zhejiang Medical Journal
关键词 内脏脂肪素心功能衰竭高敏C反应蛋白 Visfatin Heart failure High sensitivity C-reactive protein
  • 相关文献

参考文献13

  • 1Fukuhara A.Matsuda M.Nishizawa M.et al.Visfatin:a protein secre.ted by visceral fat that mimics the effects of insulin [J],Science,2005,307:426-430.
  • 2Kaser A.Ludwiczek O.Holzmann S,et al. Visfatin,an adipocytokinewith proinflammatory and immunomodulating properties[J], J Im-munol,2007, 178:1748-1758.
  • 3Chong K S, Gardner R S, Morton J J, et al .Plasma concentrationsof the novel peptide apelin are decreased in patients with chronicheart failure[J]. Eur J Heart Failure,2006, 8: 355-360.
  • 4Ho Y L, Lin Y H, Lee C M, et al.Prognostic significance of adipocy-tokines and extracellular matrix activity in heart failure patientswith high B-type natriuretic peptide[J]. Clin Biochem, 2009, 42:1407-1412.
  • 5刘圣文,乔树宾.急性冠脉综合征患者血浆内脏脂肪素水平及其影响因素研究[J].中国循环杂志,2010,25(2):104-106. 被引量:5
  • 6Straburzy n ska-Migaj E, Le^niewska K, Ochotny R(et al .Car-diopulmonary exercise testing and cytokines in chronic heart fail-ure. Comparison of patients with ischaemic and with dilated car-diomyopathy[J]. Pol Arch Med Wewn, 2004, 111: 693-701.
  • 7Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, JanowskaJ, et al.Serum concentration of visfatin in obese women [J],Metabolism, 2007,56: 1131-1134.
  • 8Jin H, Jiang B,Tang J,et al.Serum visfatin concentrations in obeseadolescents and its correlation with age and high-densitylipoprotein cholesterol[J], Diabetes Res Clin Pract, 2008,79: 412-418.
  • 9Wajchenberg 巳 L.Subcutaneous and visceral adipose tissue theirrelation to the metabolic syndrome[J].Endocr Rev,2000,21:697-738.
  • 10Aighasham A A , Bakarat Y A .(2008) Serum visfatin and its rela-tion to insulin resistance and inflammation in type 2 diabetic pa-tients with and without macroangiopathy [J], Saudi Med , 2009,29: 185-192.

二级参考文献10

  • 1Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin : a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307:426-430.
  • 2Samal B, Sun Y, Steams G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol, 1994,14 : 1431-1437.
  • 3McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet,2005,43 : 127-141.
  • 4Kaser A, Ludwiczek O, Holzmann S, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 2007,178 : 1748-1758.
  • 5Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation,2007,115 : 972-950.
  • 6Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res,2008,78 : 356-365.
  • 7Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res,2004,95 : 858-866.
  • 8Woods A, Brull D J, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease : the central role of interleukin-6. Eur Heart J,2000,21 : 1574-1583.
  • 9Pagano C, Pilon C, Olivieri M. Reduced plasma visfatin/pre-B cell eolony-enhancing factor in obesity is not related to insulin resistanee in humans. J Clin Endocrinol Metab,2006,91:3165-3170.
  • 10Chen MP,Chung FM,Chang DM,et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus. J Clin Endocrinol Metab,2006,91 : 295-299.

共引文献4

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部